WEBULL

Alignment Healthcare (ALHC) Faces Whistleblower Claims, Is The Stock Still Undervalued?

Simply Wall St · 1d ago

Whistleblower claims that Alignment Healthcare (ALHC) misclassified operating expenses as capital expenditures, allegedly inflating reported financial metrics, have prompted investigations by multiple law firms and put the stock and its accounting practices under closer scrutiny.

See our latest analysis for Alignment Healthcare.

Alignment Healthcare’s share price has come under pressure in the short term, with 1 day, 7 day and 90 day share price returns all declining. However, the 1 year total shareholder return remains strongly positive at 52.32% and the 3 year total shareholder return is very large at about 3.5x. This suggests sentiment has weakened recently as accounting allegations and insider sales reset risk perceptions.

If this kind of event driven volatility has you reassessing healthcare exposure, it can be useful to see what else is on the market with a specialist screener for 39 healthcare AI stocks

So after a sharp pullback on the whistleblower headlines, yet a 1 year return above 50% and a market value of about US$4.3b, is most of Alignment Healthcare’s upside already spent, or does the current price still leave meaningful headroom?

Most Popular Narrative: 19.6% Undervalued

On the most followed narrative, Alignment Healthcare’s fair value of $24.92 sits well above the last close at $20.03. This sets up a valuation story built around strong growth and margin assumptions.

Alignment's robust, technology-enabled care model and investments in administrative automation, workflow standardization, and digital health platforms position the company to significantly lower SG&A expenses and improve scalability, likely powering both margin expansion and earnings growth over the next several years.

Read the complete narrative. Read the complete narrative.

Want to see what kind of revenue ramp and margin profile are baked into that fair value, and how rich a future earnings multiple it relies on? The full narrative lays out specific growth rates, profitability targets and discount assumptions that explain why $24.92 is the anchor point rather than today’s $20.03.

Result: Fair Value of $24.92 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, the Alignment Healthcare narrative also leans on assumptions that could be tested if Medicare Advantage reimbursement tightens, or if competition pushes up member acquisition and medical costs.

Find out about the key risks to this Alignment Healthcare narrative.

Next Steps

With the story drawing both concerns and optimism around Alignment Healthcare, move quickly to review the numbers and weigh both sides with the 5 key rewards and 1 important warning sign

Looking for more investment ideas beyond Alignment Healthcare?

If Alignment Healthcare has sharpened your focus on where risk and reward meet, now is the time to widen your watchlist and compare it with other potential opportunities.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.